Articles published in Journal of Pharmacogenomics & Pharmacoproteomics have been cited by esteemed scholars and scientists all around the world. Journal of Pharmacogenomics & Pharmacoproteomics has got h-index 12, which means every article in Journal of Pharmacogenomics & Pharmacoproteomics has got 12 average citations.
Following are the list of articles that have cited the articles published in Journal of Pharmacogenomics & Pharmacoproteomics.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
30 | 56 | 30 | 30 | 13 | 4 | 7 | 15 | 13 | 20 | 25 | 12 | 35 | 13 | 2 |
Research, Review articles and Editorials |
0 | 6 | 2 | 4 | 1 | 1 | 6 | 14 | 12 | 17 | 25 | 12 | 34 | 7 | 2 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
30 | 50 | 28 | 8 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 | 0 | 35 | 102 | 83 | 47 | 82 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
35 | 55 | 58 | 71 | 61 | 49 | 63 | 48 | 72 | 63 | 23 | 8 | 6 | 0 | 0 |
Journal total citations count | 613 |
Journal impact factor | 2.31 |
Journal 5 years impact factor | 3.74 |
Journal cite score | 4.86 |
Journal h-index | 12 |
Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin
A pharmacometabonomic approach to predicting metabolic phenotypes and pharmacokinetic parameters of atorvastatin in healthy volunteers
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population
Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders
Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions
Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer's disease and related risk factors
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease
Gene interactions in the pharmacogenomics of Alzheimer's disease
Can cloud-based tools accelerate Alzheimer's disease drug discovery?
Pharmacogenetics of vascular risk factors in Alzheimer's disease
Genetic variants specific to aging-related verbal memory: Insights from GWASs in a population-based cohort
Pharmacogenomics of Alzheimer's and Parkinson's diseases
Opportunities in pharmacogenomics for the treatment of Alzheimer's disease
Sirtuins in alzheimer's disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics
The role of pharmacogenomics in adverse drug reactions
Pharmacogenetic considerations in the treatment of Alzheimer's disease
The broad impact of TOM40 on neurodegenerative diseases in aging
Spectrum of neuromuscular disorders with hyperCKemia from a tertiary care pediatric neuromuscular center
Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia
Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum